Automated Dialysis Anemia Management: Role of the Treating Nephrologist.
作者信息
Fishbane Steven, Shah Hitesh H
机构信息
Division of Kidney Diseases and Hypertension, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Great Neck, New York.
出版信息
Clin J Am Soc Nephrol. 2024 Sep 1;19(9):1084-1085. doi: 10.2215/CJN.0000000000000541. Epub 2024 Aug 13.
Abstract
摘要
相似文献
1
Automated Dialysis Anemia Management: Role of the Treating Nephrologist.自动化透析贫血管理：主治肾病专家的作用。
Clin J Am Soc Nephrol. 2024 Sep 1;19(9):1084-1085. doi: 10.2215/CJN.0000000000000541. Epub 2024 Aug 13.
2
Association Between Nephrologist Ownership of Dialysis Facilities and Clinical Outcomes.肾内科医生拥有透析中心与临床结局的关联。
JAMA Intern Med. 2022 Dec 1;182(12):1267-1276. doi: 10.1001/jamainternmed.2022.5002.
3
Association between primary care physician-nephrologist collaboration and clinical outcomes in patients with stage 5 chronic kidney disease: a JOINT-KD cohort study.初级保健医生与肾病专家合作与5期慢性肾脏病患者临床结局之间的关联：一项JOINT-KD队列研究
J Nephrol. 2025 May 8. doi: 10.1007/s40620-025-02299-1.
4
Methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa for anemia in non-dialysis-dependent CKD: a systematic review.甲氧基聚乙二醇-促红细胞生成素β与阿法达贝泊汀治疗非透析依赖型慢性肾脏病贫血的系统评价
Int J Clin Pharm. 2014 Dec;36(6):1115-25. doi: 10.1007/s11096-014-0023-x. Epub 2014 Oct 7.
5
The cost effectiveness of erythropoietin-stimulating agents for treating anemia in patients on dialysis: a systematic review.促红细胞生成素刺激剂治疗透析患者贫血的成本效益：一项系统评价。
Am J Nephrol. 2015;41(2):89-97. doi: 10.1159/000375541. Epub 2015 Feb 26.
6
Analysis of red blood cell lifespan and associated influencing factors in anemic dialysis patients.贫血透析患者红细胞寿命及相关影响因素分析
Ren Fail. 2025 Dec;47(1):2529439. doi: 10.1080/0886022X.2025.2529439. Epub 2025 Jul 20.
7
Market Competition and Anemia Management in the United States Following Dialysis Payment Reform.美国透析支付改革后市场竞争与贫血管理
Med Care. 2023 Nov 1;61(11):787-795. doi: 10.1097/MLR.0000000000001924. Epub 2023 Sep 18.
8
Excess morbidity in patients starting uremia therapy without prior care by a nephrologist.在未事先由肾病专家诊治的情况下开始接受尿毒症治疗的患者中存在额外的发病率。
Am J Kidney Dis. 1996 Dec;28(6):841-5. doi: 10.1016/s0272-6386(96)90383-2.
9
Recombinant human erythropoietin for chronic renal failure anaemia in pre-dialysis patients.重组人促红细胞生成素用于透析前慢性肾衰竭患者的贫血治疗
Cochrane Database Syst Rev. 2001(4):CD003266. doi: 10.1002/14651858.CD003266.
10
Effect of pre-end-stage kidney disease nephrology care on the association between neighborhood poverty and referral for kidney transplantation among patients with end-stage kidney disease.终末期肾病前期肾病护理对社区贫困与终末期肾病患者肾移植转诊之间关联的影响。
J Clin Epidemiol. 2025 Jun 24;185:111878. doi: 10.1016/j.jclinepi.2025.111878.
本文引用的文献
1
Effects of Individualized Anemia Therapy on Hemoglobin Stability: A Randomized Controlled Pilot Trial in Patients on Hemodialysis.个体化贫血治疗对血红蛋白稳定性的影响：一项针对血液透析患者的随机对照试验
Clin J Am Soc Nephrol. 2024 Sep 1;19(9):1138-1147. doi: 10.2215/CJN.0000000000000488. Epub 2024 Jun 11.
2
Artificial intelligence supported anemia control system (AISACS) to prevent anemia in maintenance hemodialysis patients.人工智能支持的贫血控制系统（AISACS）预防维持性血液透析患者贫血。
Int J Med Sci. 2021 Feb 22;18(8):1831-1839. doi: 10.7150/ijms.53298. eCollection 2021.
3
History-adjusted marginal structural analysis of the association between hemoglobin variability and mortality among chronic hemodialysis patients.慢性血液透析患者血红蛋白变异性与死亡率之间关联的历史调整边际结构分析。
Clin J Am Soc Nephrol. 2008 May;3(3):777-82. doi: 10.2215/CJN.04281007. Epub 2008 Mar 12.
4
Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin.接受重组人促红细胞生成素治疗的血液透析患者的血红蛋白循环
Kidney Int. 2005 Sep;68(3):1337-43. doi: 10.1111/j.1523-1755.2005.00532.x.
5
Effect of variability in anemia management on hemoglobin outcomes in ESRD.终末期肾病患者贫血管理的变异性对血红蛋白结果的影响。
Am J Kidney Dis. 2003 Jan;41(1):111-24. doi: 10.1053/ajkd.2003.50030.
Zotero 插件